Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer
Studies have reported the effects of the gut microbiota on colorectal cancer (CRC) chemotherapy, but few studies have investigated the association between gut microbiota and targeted therapy. This study investigated the role of the gut microbiota in the treatment outcomes of patients with metastatic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.955313/full |
| _version_ | 1811208955185070080 |
|---|---|
| author | Yen-Cheng Chen Yen-Cheng Chen Chia-Hsien Chuang Zhi-Feng Miao Kwan-Ling Yip Chung-Jung Liu Ling-Hui Li Deng-Chyang Wu Deng-Chyang Wu Tian−Lu Cheng Chung-Yen Lin Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang |
| author_facet | Yen-Cheng Chen Yen-Cheng Chen Chia-Hsien Chuang Zhi-Feng Miao Kwan-Ling Yip Chung-Jung Liu Ling-Hui Li Deng-Chyang Wu Deng-Chyang Wu Tian−Lu Cheng Chung-Yen Lin Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang |
| author_sort | Yen-Cheng Chen |
| collection | DOAJ |
| description | Studies have reported the effects of the gut microbiota on colorectal cancer (CRC) chemotherapy, but few studies have investigated the association between gut microbiota and targeted therapy. This study investigated the role of the gut microbiota in the treatment outcomes of patients with metastatic CRC (mCRC). We enrolled 110 patients with mCRC and treated them with standard cancer therapy. Stool samples were collected before administering a combination of chemotherapy and targeted therapy. Patients who had a progressive disease (PD) or partial response (PR) for at least 12 cycles of therapy were included in the study. We further divided these patients into anti-epidermal growth factor receptor (cetuximab) and anti-vascular endothelial growth factor (bevacizumab) subgroups. The gut microbiota of the PR group and bevacizumab-PR subgroup exhibited significantly higher α-diversity. The β-diversity of bacterial species significantly differed between the bevacizumab-PR and bevacizumab-PD groups (P = 0.029). Klebsiella quasipneumoniae exhibited the greatest fold change in abundance in the PD group than in the PR group. Lactobacillus and Bifidobacterium species exhibited higher abundance in the PD group. The abundance of Fusobacterium nucleatum was approximately 32 times higher in the PD group than in the PR group. A higher gut microbiota diversity was associated with more favorable treatment outcomes in the patients with mCRC. Bacterial species analysis of stool samples yielded heterogenous results. K. quasipneumoniae exhibited the greatest fold change in abundance among all bacterial species in the PD group. This result warrants further investigation especially in a Taiwanese population. |
| first_indexed | 2024-04-12T04:30:42Z |
| format | Article |
| id | doaj.art-dfade547d1624e0982da6deed9a4d72a |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T04:30:42Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dfade547d1624e0982da6deed9a4d72a2022-12-22T03:47:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.955313955313Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancerYen-Cheng Chen0Yen-Cheng Chen1Chia-Hsien Chuang2Zhi-Feng Miao3Kwan-Ling Yip4Chung-Jung Liu5Ling-Hui Li6Deng-Chyang Wu7Deng-Chyang Wu8Tian−Lu Cheng9Chung-Yen Lin10Jaw-Yuan Wang11Jaw-Yuan Wang12Jaw-Yuan Wang13Jaw-Yuan Wang14Jaw-Yuan Wang15Jaw-Yuan Wang16Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanInstitute of Information Science, Academia Sinica, Taipei, TaiwanDivision of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDivision of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, TaiwanInstitute of Information Science, Academia Sinica, Taipei, TaiwanDivision of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan0Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan1Pingtung Hospital, Ministry of Health and Welfare, Pingtung, TaiwanStudies have reported the effects of the gut microbiota on colorectal cancer (CRC) chemotherapy, but few studies have investigated the association between gut microbiota and targeted therapy. This study investigated the role of the gut microbiota in the treatment outcomes of patients with metastatic CRC (mCRC). We enrolled 110 patients with mCRC and treated them with standard cancer therapy. Stool samples were collected before administering a combination of chemotherapy and targeted therapy. Patients who had a progressive disease (PD) or partial response (PR) for at least 12 cycles of therapy were included in the study. We further divided these patients into anti-epidermal growth factor receptor (cetuximab) and anti-vascular endothelial growth factor (bevacizumab) subgroups. The gut microbiota of the PR group and bevacizumab-PR subgroup exhibited significantly higher α-diversity. The β-diversity of bacterial species significantly differed between the bevacizumab-PR and bevacizumab-PD groups (P = 0.029). Klebsiella quasipneumoniae exhibited the greatest fold change in abundance in the PD group than in the PR group. Lactobacillus and Bifidobacterium species exhibited higher abundance in the PD group. The abundance of Fusobacterium nucleatum was approximately 32 times higher in the PD group than in the PR group. A higher gut microbiota diversity was associated with more favorable treatment outcomes in the patients with mCRC. Bacterial species analysis of stool samples yielded heterogenous results. K. quasipneumoniae exhibited the greatest fold change in abundance among all bacterial species in the PD group. This result warrants further investigation especially in a Taiwanese population.https://www.frontiersin.org/articles/10.3389/fonc.2022.955313/fullmetastatic colorectal cancertargeted therapyLactobacillus speciesBifidobacterium speciesFusobacterium nucleatumKlebsiella quasipneumoniae |
| spellingShingle | Yen-Cheng Chen Yen-Cheng Chen Chia-Hsien Chuang Zhi-Feng Miao Kwan-Ling Yip Chung-Jung Liu Ling-Hui Li Deng-Chyang Wu Deng-Chyang Wu Tian−Lu Cheng Chung-Yen Lin Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Jaw-Yuan Wang Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer Frontiers in Oncology metastatic colorectal cancer targeted therapy Lactobacillus species Bifidobacterium species Fusobacterium nucleatum Klebsiella quasipneumoniae |
| title | Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer |
| title_full | Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer |
| title_fullStr | Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer |
| title_full_unstemmed | Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer |
| title_short | Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer |
| title_sort | gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer |
| topic | metastatic colorectal cancer targeted therapy Lactobacillus species Bifidobacterium species Fusobacterium nucleatum Klebsiella quasipneumoniae |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.955313/full |
| work_keys_str_mv | AT yenchengchen gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT yenchengchen gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT chiahsienchuang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT zhifengmiao gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT kwanlingyip gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT chungjungliu gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT linghuili gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT dengchyangwu gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT dengchyangwu gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT tianlucheng gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT chungyenlin gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT jawyuanwang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT jawyuanwang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT jawyuanwang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT jawyuanwang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT jawyuanwang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer AT jawyuanwang gutmicrobiotacompositioninchemotherapyandtargetedtherapyofpatientswithmetastaticcolorectalcancer |